Avalyn Pharma Inc. has set the price for its upsized initial public offering at $18.00 per share, selling 16,666,667 shares of common stock in the offering, the company said in a statement. At that price and share count, Avalyn expects to generate approximately $300 million in gross proceeds prior to subtracting underwriting discounts, commissions and offering expenses.
The Boston-based drug developer has also given the underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price, less underwriting discounts and commissions. The company said the common stock is slated to begin trading on the Nasdaq Global Select Market on April 30, 2026, and will use the ticker symbol "AVLN."
The offering is scheduled to close on May 1, 2026, pending satisfaction of customary closing conditions. Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the transaction.
Operationally, Avalyn is focused on inhaled therapeutic approaches for rare respiratory conditions. Its AP01 program is an inhaled formulation of pirfenidone currently being evaluated in a Phase 2b clinical trial for progressive pulmonary fibrosis. The companys AP02 program is an inhaled formulation of nintedanib that is in Phase 2 trials for idiopathic pulmonary fibrosis.
Regulatory filings for the offering moved forward late in April 2026: the Securities and Exchange Commission declared the registration statement effective on April 29, 2026. The company emphasized that the sale of shares will be carried out solely by means of a prospectus.
This financing round, as structured, provides Avalyn with capital intended to support its mid-stage clinical programs and related development activities. The 30-day overallotment option provides underwriters the ability to expand the offering if investor demand warrants it, while the expected Nasdaq listing sets the timetable for public trading to commence.
Summary of transaction details
- IPO price: $18.00 per share.
- Shares offered: 16,666,667 common shares.
- Gross proceeds expected: $300 million before deductions.
- Underwriter overallotment: 2.5 million shares option for 30 days.
- Expected trading start: April 30, 2026, on Nasdaq Global Select Market under "AVLN."
- Scheduled close date: May 1, 2026, subject to customary closing conditions.
The companys clinical portfolio centers on inhaled formulations of established anti-fibrotic agents, with AP01 and AP02 currently in Phase 2b and Phase 2 stages, respectively. The SECs effectiveness determination on April 29, 2026 clears the path for the planned offering to proceed through a prospectus-driven process.